April 9, 2020
Tiziana makes investigational new technology to treat COVID-19 infections
Tiziana Life Sciences said Thursday it has developed investigational new technology to treat COVID-19 infections.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Tiziana Life Sciences
September 16, 2019
Tiziana Life Sciences gets FDA approval to kick-off Phase I clinical trial with orally administered foralumab in healthy volunteers
Tiziana Life Sciences got from the U.S. Food and Drug Administration (FDA) signal to start a Phase I clinical trial in healthy volunteers using a novel oral enteric-coated capsule formulation of Foralumab, a fully human monoclonal antibody (mAb), in collaboration with the Brigham and Women’s Hospital (BWH), Harvard Medical School, Boston, MA.
July 1, 2019
Tiziana Life Science reports finding, Intravenous Treatment with Humanized Anti-CD3 mAb slows Type 1 Diabetes
Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of…
December 3, 2018
Tiziana Life Sciences completes patient enrollment for Milciclib, topline data by mid 2019
Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.
April 24, 2017
Tiziana testing drug for fifth most common cancer
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
March 14, 2017
Tiziana Life Sciences welcomes liver specialist to its Scientific Advisory Board
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
November 24, 2015
Tiziana Life Sciences places banker to its Board
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.